申请人:Emory University
公开号:US20210093597A1
公开(公告)日:2021-04-01
In certain embodiments, this disclosure relates to KRAS agonists, pharmaceutical composition, and uses in managing cancer. In certain embodiments, the KRAS agonist is 4-(4-(2-bromoacetamido)butyl)benzoic acid, salt, prodrug, or derivative thereof. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering an effective amount of a compound of Formula I,
salt, prodrug, or derivative thereof, to a subject in need thereof, wherein, substituents are reported herein.